07 December 2022 | GMT (UTC+0)
Biomarkers For NASH Symposium07 December 2022 | GMT (UTC+0)

Designed to deliver the latest insights on advancing NASH therapeutic development and diagnosis through non-invasive biomarker strategies

Our Symposiums are delivered through Swapcard, our market-leading and highly interactive digital event platform. Alongside the live programme, it has a variety of other features to maximise your event experience, including AI-assisted match-making with other delegates, additional resource such as white papers, exhibitor pages allowing you to connect with leading solution providers and a host of On-Demand content.

Download Agenda
Full details on the symposium, including the presentations, topic areas and confirmed speakers can be found in the conference brochure
Book Online

Registration for the Biomarkers For NASH Symposium is now open. Please click the button below to register for this event.

LinkedIn Group

Our LinkedIn group aims to foster discussion and collaboration between experts interested in the latest tools and strategies.


Biomarkers For NASH Symposium includes...

  • Hear from and meet with the leading figures in NASH drug development, offering innovative case studies on the latest strategies and technologies impacting NASH development and diagnosis
  • Interact with fellow attendees and speakers during the live group Q&As, allowing you to join the conversation and pose your questions to our panel of experts
  • Explore how non-invasive biomarkers can lead to improved disease measurement, tracking and monitoring, with case studies of imaging, serum biomarkers & other technologies
  • Gain insights into the development of better preclinical & translational models for NASH. Presentations also consider current NASH drug development case studies, including new targets impacting this fast-emerging therapeutic area

Agenda at a Glance

Stream 1: Preclinical & Translational Strategy for NASH

  • Preclinical development of NASH targets
  • Developing better Preclinical & translational models for NASH
  • New targets for the treatment of NASH/Fibrosis
  • Current NASH drug development case studies

Stream 2:Novel Biomarker Approaches & Technologies

  • Qualifying specific biomarkers for NASH
  • Innovation in design and analytical approaches to biomarker development
  • Advancing biomarkers for improved diagnosis
  • Novel new-invasive biomarkers: imaging & other technologies
  • Improved disease measurement, tracking and monitoring

Confirmed Speakers

The Symposium brings together a panel of prominent leaders, engineers and scientists sharing new case studies, innovative data and industry outlook for the future.

Below are some of the key speakers for our Biomarkers For NASH Symposium event

Cynthia Arbeeny

Cynthia Arbeeny


Harvey Coxson

Harvey Coxson

Boehringer Ingelheim

Adil Mardinoglu

Adil Mardinoglu

King’s College London

Jeff McIntyre

Jeff McIntyre

Global Liver Institute

AstraZeneca Logo

Richard Torstenson


Event Features​

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of virtual, remote experiences.

Virtual Presentations
& Live Q&As

Benefit from the insight of our expert speakers via live and pre-recorded presentations. Interact with fellow attendees and speakers during regular live Q&As

Digital Networking Opportunities

Connect directly with other registrants of event around the world through the robust networking tools of our online event platform

Media Partnerships

Work, research and current challenges shared by membership associations, clusters, industry researchers, and innovation networks

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.


Headline Sponsor

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated contract research, development and manufacturing services company serving the global pharma, biotech, nutrition, animal health, consumer goods and specialty chemical sectors.  

Our 4200 scientists have both the skills and the capability to deliver great science, ensure robust data management, IP security and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. 

 With 1.9 Mn sq ft of specialist discovery, development and manufacturing facilities, Syngene offers dedicated research facilities for Amgen, Baxter, Bristol-Myers Squibb and Herbalife. We also work with biotech companies pursuing leading edge science, and MNCs including GSK and Merck KGaA.  

We at Syngene have also gained considerable experience in Protein Degradation in recent years.   We currently have a team of 130 FTEs working on the synthesis of PROTACS for various clients, and we have been able to advance several drug candidates to LO and even candidate delivery stage.


Thought Leader Sponsor

BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition to develop treatments intended to extend and improve the quality-of-life of patients with life-threatening diseases. Our principal technology platform centers on targeted protein degradation, PHM® ‘molecular glues’, that enable the design of small molecules to regulate protein equilibrium. This technology is designed to utilize the body’s own protein disposal system to selectively degrade and remove disease-causing proteins. It has potential applicability to a broad range of diseases, including targets that have to date been considered ‘undruggable’

Wuxi AppTec

Headline Sponsor

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient, socially responsible and sustainable solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 4,100 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that “every drug can be made and every disease can be treated.” 

Over the last five years we have built a comprehensive platform for discovery and characterisation of bifunctional molecules, from initial hit finding activities, through characterisation with biophysical techniques and structural biology, and into in vitro and in vivo functional characterisation and DMPK. This platform is supported by several teams of synthetic organic chemists working across all classes of ligases, ligand and linker chemistries and supporting both optimisation and manufacturing activities.